Get the Stockscreener App
2.00
10.50%
0.19
After Hours:
2.04
0.04
+2.00%
Omniab Inc stock is traded at $2.00, with a volume of 1.09M.
It is up +10.50% in the last 24 hours and up +21.21% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$1.81
Open:
$1.81
24h Volume:
1.09M
Relative Volume:
2.50
Market Cap:
$287.91M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-3.937
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
+11.11%
1M Performance:
+21.21%
6M Performance:
+16.96%
1Y Performance:
-41.35%
1-Day Range:
$1.76
$2.06
1-Week Range:
$1.67
$2.06
52-Week Range:
$1.22
$3.455
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
2.00 | 260.56M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
Stifel reiterates Buy rating on OmniAb stock, cites partner growth - Investing.com
OmniAb Q4 2025 Earnings Call Transcript - MarketBeat
OmniAb Q4 Earnings Call Highlights - MarketBeat
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Earnings call transcript: OmniAb beats Q4 2025 EPS forecast, stock rises - Investing.com
OmniAb Q4 2025 slides: revenue dips but pipeline hits 407 programs - Investing.com India
OmniAb Inc (NASDAQ:OABI) Reports Q4 and Full-Year 2025 Earnings Miss, Provides 2026 Outlook - ChartMill
OmniAb Reports $50.3 Million Revenue for 2025 with 15% Annual Growth and Expanded Partnerships - geneonline.com
OmniAb (NASDAQ:OABI) Issues Earnings Results - MarketBeat
OmniAb (NASDAQ: OABI) outlines 2026 guidance after lower 2025 revenue - Stock Titan
OmniAb Q4 Earnings Assessment - Benzinga
OmniAb’s engineered chicken targets next-gen antibody drugs - Stock Titan
A Look Ahead: OmniAb's Earnings Forecast - Benzinga
OmniAb Inc (OABI) Q4 2025 Earnings Report Preview: What To Expec - GuruFocus
OmniAb Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
OmniAb (OABI) Projected to Post Earnings on Wednesday - Defense World
OmniAb to Participate at the Leerink Partners Global Healthcare Conference - BioSpace
OABIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MACD Signal: Will PFAI benefit from AI trends2025 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
Will OmniAb Inc. Equity Warrant outperform its industry peersJuly 2025 Sentiment & Verified Entry Point Detection - mfd.ru
Is OmniAb Inc. benefiting from innovation trendsEarnings Summary Report & Consistent Return Strategy Ideas - mfd.ru
Why OmniAb Inc. Equity Warrant stock is a must watch in 2025July 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - mfd.ru
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4 - BioSpace
Matthew Foehr Sells 30,843 Shares of OmniAb (NASDAQ:OABI) Stock - MarketBeat
OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 9,673 Shares - MarketBeat
Insider Selling: OmniAb (NASDAQ:OABI) CFO Sells 9,301 Shares of Stock - MarketBeat
Merger Talk: Is OmniAb Inc stock undervalued right nowPortfolio Update Report & Smart Investment Allocation Tips - baoquankhu1.vn
Surprises Report: Is OmniAb Inc benefiting from innovation trendsGlobal Markets & Free Community Supported Trade Ideas - baoquankhu1.vn
Matthew Foehr Sells 20,754 Shares of OmniAb (NASDAQ:OABI) Stock - MarketBeat
Insider Selling: OmniAb (NASDAQ:OABI) Insider Sells 6,990 Shares of Stock - MarketBeat
OmniAb (OABI) chief legal officer Berkman sells $11883 in stock By Investing.com - Investing.com South Africa
OmniAb (OABI) chief legal officer Berkman sells $11883 in stock - Investing.com Australia
Planned OABI stock sales by Charles Berkman (NASDAQ: OABI) - Stock Titan
What’s the analyst consensus on OmniAb Inc.IPO Watch & AI Forecasted Entry/Exit Points - mfd.ru
Moving Averages: Can OmniAb Inc disrupt its industryQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
What are OmniAb Inc. Equity Warrant’s recent SEC filings showingM&A Rumor & Consistent Profit Trading Strategies - mfd.ru
Is OmniAb Inc. Equity Warrant a stock for growth or value investorsJuly 2025 Update & Fast Gain Swing Trade Alerts - mfd.ru
Can OmniAb Inc. disrupt its industryTrade Risk Report & Proven Capital Preservation Tips - mfd.ru
Published on: 2026-02-10 06:32:33 - baoquankhu1.vn
Aug Swings: What analysts say about OmniAb Inc. stock2025 AllTime Highs & Verified Stock Trade Ideas - baoquankhu1.vn
Decliners Report: Is OmniAb Inc stock undervalued right nowMarket Trend Report & Daily Volume Surge Signals - baoquankhu1.vn
Dow Update: What dividend growth rate does OmniAb Inc offer2025 Trading Volume Trends & Intraday High Probability Setup Alerts - baoquankhu1.vn
Recap Report: Is AgEagle Aerial Systems Inc stock a top performer YTDIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
Targets Report: Is ClearSign Technologies Corporation being accumulated by smart money2025 Volatility Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Take Profit: Will OmniAb Inc benefit from geopolitical trendsTrade Exit Summary & High Yield Stock Recommendations - baoquankhu1.vn
Market Review: Is OmniAb Inc Equity Warrant a stock for growth or value investorsMarket Growth Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Published on: 2026-02-02 07:00:49 - baoquankhu1.vn
Momentum Shift: How is The New York Times Company managing supply chain issues2025 Volume Leaders & Daily Technical Stock Forecast Reports - baoquankhu1.vn
US Market Recap: Can EVGOW continue delivering strong returnsWeekly Trade Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Resistance Check: Does Equus Total Return Inc align with a passive investing strategyQuarterly Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
OmniAb Updates Bylaws to Align with SEC Proxy Rules - TipRanks
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Berkman Charles S | Chief Legal Officer |
Feb 18 '26 |
Sale |
1.71 |
9,673 |
16,541 |
392,700 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Feb 18 '26 |
Option Exercise |
0.00 |
18,750 |
0 |
278,152 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Feb 18 '26 |
Sale |
1.71 |
9,301 |
15,905 |
268,851 |
| FOEHR MATTHEW W | President and CEO |
Feb 18 '26 |
Sale |
1.71 |
30,843 |
52,742 |
4,403,277 |
| FOEHR MATTHEW W | President and CEO |
Feb 16 '26 |
Option Exercise |
0.00 |
36,458 |
0 |
4,396,541 |
| FOEHR MATTHEW W | President and CEO |
Feb 17 '26 |
Sale |
1.70 |
20,754 |
35,282 |
4,375,787 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
266,230 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Feb 17 '26 |
Sale |
1.70 |
6,828 |
11,608 |
259,402 |
| Berkman Charles S | Chief Legal Officer |
Feb 16 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
390,613 |
| Berkman Charles S | Chief Legal Officer |
Feb 17 '26 |
Sale |
1.70 |
6,990 |
11,883 |
383,623 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):